Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

TGF-ß1 and IL-10 expression in epithelial ovarian cancer cell line A2780

Xin Feng^1,2 , Cai-Xia Wang³, Zhi-Ying Ou⁴

¹Department of Gynecologic, Oncology Cancer Center Southern Medical University, Guangzhou, China; ²Department of Gynecologic, Guangzhou Women and Children's Medical Center, Guangzhou Medical College, Guangzhou, China; ³Department of Gynecology and ObstetricsA292;Guangdong Provincial Corps Hospital, Chinese People Armed Forces, Guangzhou 51507, China; ⁴Guangzhou Women and Children's Medical Center, Affiliate of Guangzhou Medical College, Guangzhou 510623, China.

For correspondence:- Xin Feng Email: fengxin142@gmail.com Tel:+862061640114

Received: 20 July 2015 Accepted: 24 October 2015 Published: 27 December 2015

Citation: Feng X, Wang C, Ou Z. TGF-ß1 and IL-10 expression in epithelial ovarian cancer cell line A2780. Trop J Pharm Res 2015; 14(12):2179-2185 doi: 10.4314/tjpr.v14i12.4

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: Ovarian cancer is a leading cause of death among gynaecological malignancies. Transforming growth factor-beta 1 (TGF-β1) and interleukin-10 (IL-10) are cytokines in the tumour microenvironment and may play critical roles in immune suppression. This study highlights these roles and immunosuppressive functions in epithelial ovarian cancer (EOC).

Methods: TGF-β1 and IL-10 expression was compared in malignant, benign, and borderline cancerous tissues and tumour-free tissue by immunohistochemistry. Relationships among the levels of these cytokines, correlation of expression level with EOC prognosis, and cytokine involvement in immunosuppression were investigated.

Results: Immunohistochemical analysis of TGF-β1 and IL-10 in epithelial cells showed the presence of epithelial, borderline, and benign ovarian tumour growth, and normal ovarian growth. TGF-β1 (P = 0.121), residual tumour after surgery (P = 0.231) and standard chemotherapy (P = 0.121) were prognostic factors for EOC. There were no significant differences in clinicopathologic factors between specimens expressing TGF-β1 at low and high levels, indicating that TGF-β1 is an independent factor in EOC diagnosis. Higher concentrations of TGF-β1 (1754.690 ± 3416.487 pg/ml) and IL-10 (2731.7101 ± 6.1613 pg/ml) were observed in A2780-conditioned than in control medium.

Conclusion: TGF-β1 and IL-10 play pivotal roles in EOC and can lead to immune evasion. Targeting these cytokines for tumour treatment, specifically at early stages, may prevent tumour progression.